Sunday, July 15, 2012

'Ice Age 4' Lukewarm Domestic $45.5M Weekend; Hotter $300M Global By Monday; 'Spider-Man' Holds -44%

Sony's successful The Amazing Spider-Man 3D reboot came in at around $35M this weekend with a good -44% hold and a cume passing $200M sometime Sunday. A week after opening, Spidey hit $400M worldwide and Sony is confident it will end up around $800M. (Interesting how Spidey or Scrat were either #1 or #2 in international theaters country by country last weekend.) There's no doubt this franchise restart with another origins story for Marvel's most popular character is a success, even if it didn't break box office records or reinvent the genre or even please fanboys. So Sony Pictures Entertainment chairman Amy Pascal and vice chairman Jeff Blake deserve kudos for taking a risk.

Here's the rest of the Top Ten ranked according to weekend estimates:

1. Ice Age 4 3D (Blue Sky/Fox) NEW [3,879 Theaters] PG
Friday $16.5M, Saturday $16.5M, Weekend $45.5M

2. Amazing Spider-Man 3D (Col/Sony) Week 2 [4,318 Theaters] PG13
Friday $10.3M, Saturday $14M, Weekend $35M (-44%), Cume $200.9M

3. Ted (Universal) Week 3 [3,303 Theaters] R
Friday $6.9M, Saturday $8.9M, Weekend $23.0M, Cume $159.8M

4. Brave 3D (Pixar/Disney) Week 4 [3,392 Theaters] PG
Friday $3.4M, Saturday $4.4M, Weekend $10.9M, Cume $195.8M

5. Magic Mike (Warner Bros) Week 3 [3,090 Theaters] R
Friday $3.2M, SaturdayWeekend $8.5M, Cume $91.5M

6. Savages (Universal) Week 2 [2,635 Theaters] R
Friday $2.7M, Saturday $3.7M, Weekend $9.2M (-42%), Cume $31.9M

7. Madea's Witness Protection (TPerry/Lgate) Week 3 [2,004 Theaters]
Friday $1.7M, Saturday $2.4M, Weekend $5.7M, Cume $55.5M

8. Katy Perry 3D (Insurge/Paramount) Week 2 [2,732 Theaters] PG
Friday $1.3M, Saturday $1.4M, Weekend $3.7M, Cume $18.6M

9. Madasgascar 3 3D (DWA/Par) Week 6 [2,285 Theaters] PG
Friday $1.0M, Saturday $1.5M, Weekend $3.5M, Cume $203.8M

10. Moonrise Kingdom (Focus Features) Week 7 [924 Theaters] PG13
Friday $1.0M, Saturday $1.4M, Weekend $3.4M, Cume $32.2M



No comments:

Post a Comment